Kohita H, Matsushita Y, Moriguchi I
School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan.
Chem Pharm Bull (Tokyo). 1994 Apr;42(4):937-40. doi: 10.1248/cpb.42.937.
The binding of carprofen (CP) to human serum albumin (HSA) and bovine serum albumin (BSA) was compared using equilibrium dialysis method. The affinity of CP for the primary binding site was BSA > HSA. However, the number of primary binding sites (n1) was 1.94 on HSA, considerably greater than that on BSA (0.79). The displacement of the binding of CP to HSA and BSA was studied in the presence of phenylbutazone (PB, site I marker), ibuprofen (IB, site II marker) or 2,3,5-triiodobenzoic acid (TIB, both site I and II marker). The binding of CP to HSA was altered by PB, IB and TIB, while the binding of CP to BSA was not changed by PB, although it was reduced by IB and TIB. These results suggested that, for the binding of CP, HSA has two major sites (site I and site II), whereas BSA has a single primary site (site II). The binding characteristics of 2-anthracenecarboxylic acid with HSA and BSA were found quite similar to those of CP. Thus, it seemed that long, planar compounds with a carboxyl group at one end can bind to site I and site II on HSA, but only to site II on BSA. The difference between HSA and BSA in the affinity of site I may be due to the difference in the basic and hydrophobic amino acid residues.
采用平衡透析法比较了卡洛芬(CP)与人血清白蛋白(HSA)和牛血清白蛋白(BSA)的结合情况。CP对主要结合位点的亲和力为BSA>HSA。然而,HSA上主要结合位点的数量(n1)为1.94,远多于BSA上的数量(0.79)。在存在保泰松(PB,位点I标记物)、布洛芬(IB,位点II标记物)或2,3,5-三碘苯甲酸(TIB,位点I和位点II标记物)的情况下,研究了CP与HSA和BSA结合的置换情况。PB、IB和TIB改变了CP与HSA的结合,而PB未改变CP与BSA的结合,尽管IB和TIB使其结合减少。这些结果表明,对于CP的结合,HSA有两个主要位点(位点I和位点II),而BSA有一个主要位点(位点II)。发现2-蒽羧酸与HSA和BSA的结合特征与CP非常相似。因此,似乎一端带有羧基的长平面化合物可以与HSA上的位点I和位点II结合,但只能与BSA上的位点II结合。HSA和BSA在位点I亲和力上的差异可能是由于碱性和疏水氨基酸残基的差异。